Sequential proteolytic cleavages of amyloid-b protein precursor (AbPP) by b-secretase and g-secretase generate amyloid b (Ab) peptides, which are thought to contribute to Alzheimer's disease (AD). Much of this processing occurs in endosomes following endocytosis of AbPP from the plasma membrane. However, this pathogenic mode of processing AbPP may occur in competition with lysosomal degradation of AbPP, a common fate of membrane proteins trafficking through the endosomal system. Following up on published reports that LINGO-1 binds and promotes the amyloidogenic processing of AbPP we have examined the consequences of LINGO-1/AbPP interactions. We report that LINGO-1 and its paralogs, LINGO-2 and LINGO-3, decrease processing of AbPP in the amyloidogenic pathway by promoting lysosomal degradation of AbPP. We also report that LINGO-1 levels are reduced in AD brain, representing a possible pathogenic mechanism stimulating the generation of Ab peptides in AD.
A lzheimer's disease (AD) is associated with aberrant accumulation of b-amyloid (Ab), a peptide produced by proteolytic processing of the b-amyloid precursor protein (AbPP) (1Á3). AbPP, a membrane protein, is subject to cleavage within its extracellular domain by a-or b-secretases, triggering cleavage within its transmembrane domain by g-secretase. The b/g cleavage sequence produces Ab while the a/g sequence produces the p3 peptide, commonly believed to be innocuous. Processing may occur during trafficking through the ER/ Golgi compartments of the secretory pathway, or following trafficking to the cell surface (4Á7). Most nascent AbPP molecules are cleaved by a-secretase in either the Golgi or a post-Golgi/plasma membrane compartment to produce soluble extracellular domain sAbPPa and an intracellular carboxy-terminal fragment (CTFa). AbPP is subject to rapid clathrin-mediated endocytosis, minimizing the life-time of the intact protein at the cell surface (8) . Internalized AbPP then enters late endocytic compartments where cleavage by b-secretase produces sAbPPb and CTFb, and cleavage of CTFb by g-secretase produces Ab peptides (7Á9). Ab production may also occur via direct Golgi to endosome trafficking (7, 10) . Several membrane proteins act as sorting receptors that bind AbPP controlling its endocytosis and endosomal trafficking, thereby influencing production of Ab peptides, such as LRP1, LRP1b (11), ApoER2 (9) and SorLA (12) .
Using crosslinking to identify the in vivo interactions of AbPP, Bai and colleagues demonstrate that LINGO-1, a membrane protein, physically associates with AbPP in cortical neurons and that this interaction stimulated Ab generation from AbPP, by increasing the production of CTFb while decreasing production of CTFa (13) . Partially contradicting these findings, a subsequent study lead to the conclusion that LINGO-1 over-expression decreased levels of both CTFb and CTFa (14) . Neither study elucidated the mechanism of the reported effects of LINGO-1.
LINGO-1 is evolutionarily related to LRIG-1, a membrane protein that promotes the endocytosis and lysosomal degradation of a variety of membrane proteins, including receptor tyrosine kinases such as the EGF, HGF and GDNF receptors (15) . This observation led us to initiate experiments to examine whether effects of LINGO-1 on AbPP processing occurs due to altered trafficking of AbPP through the endosome/lysosome pathway. Bai and coworkers employed C-terminally tagged LINGO-1 in their experiments examining the influence of LINGO-1 on AbPP processing. Our studies have revealed that C-terminal tags functionally disrupt a C-terminal domain that controls the trafficking of LINGO-1 between plasma membrane and intracellular membrane compartments (unpublished observations). Thus we employed LINGO-1 lacking C-terminal tags for our studies.
Our studies confirm that LINGO-1 does interact physically and functionally with AbPP. We find this association promotes the lysosomal degradation of AbPP by a non-amyloidogenic pathway suggesting that LINGO-1 deficiency might increase the proportion of AbPP processed by the amyloidogenic pathway. Indeed, we report that LINGO-1 expression in cortical grey matter is substantially reduced in individuals with AD, as compared to cognitively normal subjects.
Materials and methods
Vector construction pRRL-cPPT-CMV-hLINGO-1-IRES-hrGFPII-PRE-SIN. We thank Dr. William Osborne for providing the lentiviral transfer vector pRRL-cPPT-CMV-X-PRE-SIN. Full length LINGO-1 was isolated from IMAGE clone 4214 343 using HindIII restriction enzyme. The digest was heat inactivated at 658C for 20 min and the ends blunted with T4 DNA polymerase. This second reaction was heat inactivated at 758C for 20 min and then further digested with EcoR1. The cut product (2,350 bp) was run on a 1% agarose gel and band purified. The fragment was ligated into an EcoR1 and EcoR5 linearized pRRL-cPPT-CMV-X-PRE-SIN. Confirmation of gene insertion was obtained by direct sequencing of the final product.
Cell culture, transfection and treatments HEK293 and N2A cells were cultured in pH 7.2 DMEM (MediaTech) containing 10% fetal bovine serum (FBS) (Hyclone) at 378C, 5% CO 2 . Both HEK293 cells and N2A cells were plated at 30Á50% confluency in 6-well plates 24 h prior to transfection. Cells were transfected using Lipofectamine 2000 (2.5 ml/mg LIPO:DNA; Invitrogen) and 1 mg (unless otherwise indicated) of plasmid DNA (per construct transfected) in DMEM containing 10% FBS without antibiotics. Cells transfected with expression vectors were harvested 24 h post-transfection while cells transfected with siRNA were harvested 48 h post-transfection. Cells plated on cover slips were plated at 20Á30% confluency. Cells transfected with siRNA were transfected with 2 ml/well of Lipofectamine 2000 and 50 nM siRNAs. Where indicated, cultures were subjected to the following treatments in fresh media: DMSO (Sigma, 1:1000, times vary), DAPT (Sigma, 10 mM, 20 h), bafilomycin a1 [Baf] (Calbiochem, 0.1 mm, 12 h), epoxomicin [Epo] [EMD, 1 mM, 6 h, a concentration found to be non-toxic in previous studies (16) ].
Brain tissue sample preparation Post-mortem human brain samples were obtained from the University of Washington Neuropathology Core and Alzheimer Disease Research Center (ADRC). The University of Washington Human Subjects Division determined that our use of these coded specimens did not meet the federal definition of research with human subjects under 45 CFR 46. Sections of frozen cortical grey matter were isolated, weighed, and added to a microcentrifuge tube. A matching volume of lysis buffer [20 mM Tris, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 250 mM sucrose, and protease inhibitor mixture (Sigma)] was added to each tube and the sample was gently prepared using a microcentrifuge tube pestle. The samples were triturated by passing them through a 20 gauge needle to sheer DNA. The processed lysate was then sonicated for 10 pulses at 20% duty/output #2 before being clarified by centrifugation (16,000 g, 15 min at 48C). The final clarified supernatant was collected and protein concentrations for each sample were quantified by Bradford assay for use in SDS-PAGE. SDS loading buffer (62 mM Tris pH 6.8, 2% SDS, 10% Glycerol, 2% BME, 0.02% BPB) was added to the lysates and they were boiled for five minutes.
Dissociated mouse primary neuronal culture All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Washington and conform to the National Research Council's guide for the care and use of laboratory animals. C57Bl6 mice of both sexes, were housed in the AALAC approved vivarium of the University of Washington. Neonatal mice were sacrificed by decapitation for harvest of brain tissue. Primary cortical neurons were prepared from postnatal day zero mouse pup brains. Pup brains were removed in Hanks' medium without Ca 2 ' and Mg 2 , and then further dissected in dissection media (Neurobasal-A TM (Invitrogen) medium supplemented with 10 mm HEPES, and 500 mM L-glutamine). After the dissection, cortices were digested with 3.75 mg/ml trypsin for 25 min at 378C. The trypsin digestion was halted with trypsin inhibitors and the tissue was treated with 1 mg/ml DNase (Sigma). The tissue was dissociated by multiple rounds of pipetting and collected by centrifugation at 800 rpm for 3 min. The neurons were resuspended in dissection media and the process repeated three times to wash the neurons. On the final wash the neurons were resuspended in plating media (Neurobasal-A TM with B27 supplement and 500 mM L-glutamine). The neurons were plated on poly-d-lysine (Sigma, 0.1 mg/ml in dH 2 O) coated 12 well plates. The neurons were allowed to recover for 2Á3 days before transduction with virus or transfection with siRNA. Transduced neurons were cultured for 5 days without changing the media, while siRNA transfected neurons were harvested after 48 h. Neuronal cultures were transduced using 3 MOI of virus in serum free media. For experiments using the g-secretase inhibitor DAPT, cells were treated with 10 mM DAPT starting approximately 24 h after transfection and remained in the inhibitors for 16Á20 h prior to lysis.
Immunocytochemistry
Cover slips were rinsed twice with phosphate-buffered saline (PBS, pH 7.4) and fixed with 4% formaldehyde in PBS for 10 min. Cover slips were then rinsed with PBS and permeabilized (0.25% v/v Triton-X100 in PBS for 15 min) before blocking in 10% w/v bovine serum albumin in PBS (BSA/PBS) for 10 min. The cover slips were then incubated overnight at 48C with primary antibodies. Primary antibody dilutions used the following: rabbit anti-LINGO-1 (Upstate, 1:1000) and mouse anti-LINGO-1 (R&D, 1:500). Primary antibodies were removed and cover slips were rinsed four times with PBS. The cover slips were incubated in secondary reagents for 45 min (Molecular Probes; Alexafluor 594, 1:1000 and Alexafluor 488, 1:1000) at room temperature or 3 h at 48C. The cover slips were then washed twice with PBS and once with deionized water before mounting in Vectashield with DAPI (Vector Labs).
Confocal microscopy
Confocal images of cultured mouse neurons or human cortex were acquired on a Nikon Eclipse Ti confocal microscope using 405 nm, 488 nm and 543 nm excitation lasers. Images were obtained at 40 )/0.65 NA. Emission channels were sequentially acquired in frame-scan mode with line averaging (set to 4). The final multi-channel image was reconstructed using the microscope's resident imaging software package, NIS-Elements.
g-secretase activity assay APP-Gal4-VP16 expression construct was employed to measure g-secretase activity in a variety of cell types. This construct reports the AbPP-cleavage dependent expression of luciferase and the independent constitutive expression of b-galactosidase, thereby allowing for luciferase activity levels to be normalized to transfection efficiency. HEK 293 or N2A cells were plated at 50,000 cells/well in a 24 well plate the day prior to transfection with APP-Gal4-VP16 and LINGO constructs. The cells were then grown for 72 h and then rinsed twice with icecold PBS and lysed in 100 ml of cold lysis buffer (0.1% Triton X-100, 1 mM DTT, 6 mM MgSO4, 4 mM ATP, 100 mM potassium phosphate, pH 7.8) and the plates were frozen at Á808C to promote lysis. Each well of a 96-well microtiter white bottomed plate was filled with 200 ml (100 mM potassium phosphate, 6 mM MgSO4/4 mM ATP, pH 7.8) and 25 ml lysates added to each well. Luciferase activity was then determined by employing a Berthold EG&G MicroLumat LB 96 V luminometer. The raw output from the luminometric assays were normalized to the constitutive and transfection-dependent bGal value for each sample. Cells were transfected using Lipofectamine 2000 and 1 mg of appropriate expression construct.
Immunoblot analysis
Cells were washed twice with cold PBS on ice, lysed in 20 mM Tris, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 250 mM sucrose, and protease inhibitor mixture (Sigma), and centrifuged 15 min at 16,000)g. The resulting clarified supernatants were quantified by Bradford assay for use in SDS-PAGE. SDS-PAGE, semi-dry transfer using 0.45 mm PDVF (Millipore) were performed as previously described (17) . The resulting membranes were blocked with 0.01% Tween-20, phosphate-buffered saline (PBS-T) containing 5% non-fat dried milk for 1 h at room temperature and then probed with primary antibody overnight at 48C. After washing, membranes were incubated with horseradish peroxidase-conjugated secondary IgG (Jackson Immuno, 1:20,000) in 5% milk, PBS-T for 1 h at room temperature. After exposure to the secondary antibody, membranes were further washed and treated with ECL (0.2 mM coumaric acid, 1.25 mM Luminol, 1 mM Tris activated with 0.12% hydrogen peroxide in water). Densitometry of resulting target bands was performed using NIH ImageJ.
Statistics
Unless otherwise indicated, statistical significance was evaluated using Student's t-test. Error bars for luciferase activity represent standard error of the mean. 
Results
LINGO-1 diminishes g-secretase-mediated processing of AbPP Our initial experiments sought to confirm that LINGO-1 influences processing of AbPP. Quantitation of Ab peptide production from AbPP is fraught with difficulty. Multiple AbPP-derived peptides are produced with varying length thereby affecting the reactivity with antibodies employed for immunoassay, and likely, varying the extractability from lysed cells. Consequently, we have employed a procedure that monitors g-secretase mediated release of the intracellular domain (AICD) of AbPP, since release of Ab peptides from AbPP by g-secretase is accompanied by release of AICD (16, 18) . The methodology involves expression of AbPP modified by C-terminal fusion to a transcription factor, so that AICD release drives expression of a luciferase reporter gene. We examined the effect of LINGO-1 on AICD release using this reporter system. We have observed that mutation of residues at the C-terminus of the intracellular domain of LINGO-1 causes LINGO1 to traffic to the cell surface, in contrast to native LINGO-1 which is restricted to intracellular membrane compartments (unpublished results). Thus we used LINGO-1 mutated in this manner as a negative control. We found that LINGO-1 dramatically decreased release of AICD both in a non-neuronal cell line (HEK293) and in a neuronal cell line (N2A) while LINGO-1 bearing a C-terminal deletion mutation had little effect (Fig. 1) .
LINGO-1 has three paralogs, LINGO-2, LINGO-3, and LINGO-4, which are similar in amino acid sequence (44Á60% identical) and domain structure to LINGO-1. LINGO-2 and LINGO-3, like LINGO-1, are expressed in cortical neurons. This begs the question whether LINGO-1 paralogs also diminish release of AICD from AbPP. The data in Fig. 1 indicate that LINGO-3 affects production of AICD almost as strongly as LINGO-1 while LINGO-2 is substantially less effective.
LINGO-1 binds AbPP
The apparent inconsistency of our finding that LINGO-1 diminishes g-secretase mediated processing of AbPP with previously reported enhancement of Ab production by LINGO-1 caused us to assess whether published reports that LINGO-1 binds AbPP are correct. In order to assess whether LINGO-1 associates with AbPP, we expressed the two proteins by transient transfection of HEK 293 cells, and assessed whether LINGO-1 was present in AbPP immunoprecipitates. This experiment revealed an avid association of LINGO-1 with AbPP (Fig. 2) . Similarly, AbPP was detected in LINGO-1 immunoprecipitates (data not shown).
LINGO-1 down-regulates AbPP
In the experiment illustrated in Fig. 2 , we noted that expression of LINGO-1 substantially reduced the amount of AbPP present in cell lysates. Furthermore, LINGO-1 diminished the amount of CTF, the C-terminal product of cleavage of AbPP by a-and b-secretases. (The similarly sized products of a and b cleavage were not well-resolved in this experiment). Reduced CTF accumulation could result from increased cleavage of CTF by g-secretase.
However, in the presence of the g-secretase inhibitor, DAPT, LINGO-1 still strongly down-regulated the AbPP CTF. The results indicate that LINGO-1 promotes degradation of AbPP and CTF by a g-secretase-independent pathway.
To examine this effect more systematically, we employed transient transfection with increasing quantities of LINGO-1 plasmid to assess whether the effect of LINGO-1 was dose-dependent. We observed that the amount of AbPP present in cells varied in inverse proportion to the amount of LINGO-1 expressed (Fig. 3) . As a control to verify that AbPP down-regulation resulted from increased LINGO-1 expression rather than a non-specific effect of LINGO-1 plasmid, we verified that shRNA-mediated knockdown of LINGO-1 expression blocked the effect of LINGO-1 plasmid transfection on AbPP expression (Fig. 4) .
LINGO-1 paralogs down-regulate AbPP
In light of our observation that the various LINGO-1 paralogs differed in their ability to reduce release of the AICD fragment of AbPP, we compared the effects of LINGO-1, LINGO-2 and LINGO-3 on AbPP downregulation. We found that LINGO-1, LINGO-2 and LINGO-3 each down-regulated AbPP (Fig. 5) . Although LINGO-2 was slightly less effective than the other paralogs, the differential effect of LINGO-2 was not as great as observed in the prior experiment assessing effects on production of AICD. However, this difference might simply reflect differing levels of LINGO-2 expression achieved in the two experiments.
LINGO-1 down-regulates AbPP in cortical neurons
The prior experiments all employed AbPP artificially expressed in cell lines. In order to determine whether LINGO-1 has a similar effect on endogenous AbPP in authentic neurons, we exposed cultured cortical neurons to a lentiviral vector expressing LINGO-1. The results demonstrated that LINGO-1 overexpression down-regulates endogenous AbPP in cortical neurons (Fig. 6) .
Since LINGO-1 down-regulates AbPP both when it is expressed from its native promoter and when it is expressed artificially from a constitutively active CMV promoter, it is unlikely that LINGO-1 acts by transcriptional regulation. Instead, it seems likely that LINGO-1 promotes AbPP degradation. Major cell pathways for protein turnover include degradation by lysosomes and degradation by proteasomes. Because of the structural similarity of LINGO-1 to LRIG1, which promotes lysosomal degradation of several membrane proteins, we hypothesized that LINGO-1 promotes lysosomal degradation of AbPP. We tested this hypothesis employing a pharmacological inhibitor of lysosome (bafilomycin a1) and compared the effect to the effect of a pharmacological inhibitor of proteasomes (epoxomicin), which represents another major cellular pathway for protein degradation (Fig. 7) . The down-regulation of AbPP mediated by transduced LINGO-1 overexpression in neurons was not rescued by treatment with the proteasome inhibitor epoxomicin. However, AbPP expression was strongly elevated above control levels when transduced cultures were treated with the lysosome inhibitor bafilomycin a1, indicating that lysosomes mediate LINGO-1 dependent degradation of AbPP. Lysosomal inhibition also blocked LINGO-1-mediated down-regulation of endogenous AbPP expressed in HEK 293 and N2A cells (data not shown).
These results suggest that eliminating expression of endogenous LINGO-1 in cultured cortical neurons would up-regulate AbPP. Unfortunately, we were unable to test this hypothesis because our efforts to knock down expression of LINGO-1 with siRNAs were confounded by the fact that non-specific control siRNAs massively upregulated LINGO-1 (data not shown). It is well known that siRNAs act non-specifically to activate toll-like receptors (19, 20) so we suspect that the effect of siRNAs on LINGO-1 expression reflects transcriptional regulation by effectors such as NF-kB that function down-stream of toll-like receptors.
LINGO-1 localization in cortical neurons
To assess the potential of LINGO-1 to act as a physiological regulator of AbPP turnover in brain cortex, we asked whether LINGO-1 and AbPP are co-expressed in the same neuronal cell types and in similar subcellular compartments. In situ hybridization data localizing LINGO-1 and AbPP mRNA in the developing mouse brain (21) indicate that LINGO-1 and AbPP are expressed in similar populations of brain neurons, particularly in the cortex. We employed immunofluorescence microscopy to compare the distribution of LINGO-1 and AbPP in cerebral cortex. To ensure that the immunostaining observed was specific, we compared results with two different LINGO-1 antibodies, directed against the N-terminus or C-terminus of LINGO-1. In preliminary experiments immunostaining HEK293 cells transfected with LINGO-1, LINGO-2 or LINGO-3 we observed that the antibody against LINGO-1 C-terminus recognized LINGO-2 and LINGO-3 equally well, while the antibody against LINGO-1 N-terminus did not recognize LINGO-2 or LINGO-3. We observed that the two antibodies immunostained identical intracellular membrane compartments, and in the same cortical neurons in histological sections of human cortex and in neonatal mouse cortical neuronal cultures (Fig. 8) . These results support the conclusion that both antibodies are specific. The results also suggest that LINGO-1 is the predominant LINGO isoform in cortex. This conclusion was confirmed by immunopreciptating a mouse cortical homogenate with the pan-specific LINGO-1 antibody, followed by analysis of the immunoprecipitated proteins by mass spectrometry. Peptide fragments identified derived almost exclusively from LINGO-1 (data not shown).
We employed the antibody against the C-terminus (ICD) of LINGO-1 to compare the distribution of AbPP and LINGO-1 in cultured mouse cortical neurons (Fig. 9) . The images revealed that most cortical neurons express both and AbPP and LINGO-1. LINGO-1 levels are reduced in AD brain cortex Our results indicating that LINGO-1 down-regulates AbPP by a non-amyloidogenic pathway suggest that the level of LINGO-1 expression in the brain might be a determinant of risk to develop AD. For this reason, we performed immunoblot experiments to assess whether LINGO-1 expression in parietal, frontal and temporal cortical grey matter from AD brains differs from agematched normal subjects. Sample volumes of detergent brain extracts were adjusted to ensure that equivalent amounts of protein were loaded for each brain sample, and gel immunoblots were quantified densitometrically for LINGO-1 and b-tubulin. LINGO-1 expression was normalized to b-tubulin levels. Relative to controls, LINGO-1 levels were reduced by almost 50% in AD cortical samples (Fig. 10) . This effect was observed in all three cortical regions examined.
Discussion
Our results indicate that LINGO-1 interaction with AbPP promotes lysosomal degradation of AbPP. Degradation in this manner reduces the opportunity for AbPP to undergo processing by the amyloidogenic pathway. LINGO-3 and, to a lesser extent, LINGO-2 appears to have the capacity to function redundantly with LINGO-1 in promoting degradation of AbPP but LINGO-1 mediated AbPP degradation probably predominates in cortex where LINGO-1 is the most abundant member of the LINGO family. However, the extent to which the various LINGO paralogs may function redundantly in cortical regulation of AbPP remains to be determined more fully.
Analysis of the interaction of deletion mutants of AbPP has indicated that neither the leucine rich repeat domain, the transmembrane domain, or the cytoplasmic domain of LINGO-1 are required for association with AbPP, Fig. 9 . LINGO and AbPP are co-expressed in mouse cortical neurons. Confocal immunofluorescence microscopy was employed to localize LINGO-1 (red) and AbPP (green) in cultured neonatal mouse cortical neurons. Blue is DAPI nuclear stain. Scale bar equals 50 mm. implying that the binding domain lies in the C-terminal portion of the extracellular domain (22) . Our results indicate that the intracellular domain of LINGO-1 is required for effective stimulation of AbPP degradation. We speculate that the cytoplasmic domain of LINGO-1 interacts with cytoplasmic proteins that control trafficking through the secretory and/or endolysosomal pathway.
Following endocytosis, AbPP is apparently degraded by two alternative pathways, one involving lysosomal degradation, and the other involving sequential cleavage by aor b-and g-secretase. The consistently lower LINGO-1 levels we observed in post-mortem samples of cortex from individuals with AD compared to controls would be predicted to increase the proportion of AbPP processed by the amyloidogenic pathway and thereby promote the progression of neurodegeneration. The mechanism responsible for the reduction of LINGO-1 levels in AD brains remains to be determined. However, it is likely that the mechanism concerns altered transcriptional regulation. It has been reported that the glutamate agonist kainic acid transcriptionally up-regulates expression of LINGO-1 (23). Consequently we speculate that the decreased cortical activity that characterizes AD may be responsible for the decrease in LINGO-1 expression.
LINGO-1 has not been identified directly as a genetic risk factor for AD. However, genetic linkage studies have identified specific alleles of both LINGO-1 and LINGO-2 as risk factors for another common neurodegenerative disease, essential tremor and more controversially, Parkinson's disease (24Á30). Individuals with essential tremor and Parkinson's disease have increased risk for AD (31) . The role of LINGO-1 in regulating AbPP processing by shunting it from a pathogenic to a non-pathogenic proteolytic pathway may point the way to novel means of therapeutically reducing production of Ab peptides in AD.
